EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study

Yuri Cho iD, Jeong-Hoon Lee iD, Baek-Yeol Ryoo iD, Ho Yeong Lim iD, Dong Eun Lee iD, Bo Hyun Kim iD, Joong-Won Park iD

Gut and Liver · 15.07.2026 · 20 (4) · 624-635

DOI: 10.5009/gnl250532 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Gut and Liver, online erschienen am 07.04.2026. Verfasst von Yuri Cho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularBevacizumabAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleProspective StudiesPhenylurea CompoundsMiddle AgedQuinolinesAgedPyridinesSorafenibProgression-Free SurvivalKaplan-Meier EstimateRepublic of KoreaTreatment OutcomeAdult

Stichwörter der Autor:innen

Atezolizumab plus bevacizumabHepatocellular carcinomaLenvatinibSecond-line treatmentSorafenib

Substanzen

BevacizumabAntibodies, Monoclonal, HumanizedatezolizumabPhenylurea CompoundsQuinolineslenvatinibPyridinesSorafenibregorafenib

Autor:innen und Institutionen

  • Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.
  • Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
  • Biostatistics Collaboration Team, Research Institute, National Cancer Center, Goyang, Korea.

ORCID-Profile: Yuri Cho, Jeong-Hoon Lee, Baek-Yeol Ryoo, Ho Yeong Lim, Dong Eun Lee, Bo Hyun Kim, Joong-Won Park

Zitieren

APA

Cho, Y., Lee, J. H., Ryoo, B. Y., Lim, H. Y., Lee, D. E., Kim, B. H., & Park, J. W. (2026). Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study. Gut and Liver, 20(4), 624-635. https://doi.org/10.5009/gnl250532

Vancouver

Cho Y, Lee JH, Ryoo BY, Lim HY, Lee DE, Kim BH, et al. Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study. Gut and Liver. 2026;20(4):624-635. doi:10.5009/gnl250532

BibTeX
@article{Cho2026,
  author = {Cho, Yuri and Lee, Jeong-Hoon and Ryoo, Baek-Yeol and Lim, Ho Yeong and Lee, Dong Eun and Kim, Bo Hyun and Park, Joong-Won},
  title = {Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study},
  journal = {Gut and Liver},
  year = {2026},
  volume = {20},
  number = {4},
  pages = {624--635},
  doi = {10.5009/gnl250532}
}
Kostenlos starten →